Capvizr
THE DEAL, AT A GLANCE

PurpleLab

From the announcement
01Who is involvedBacked by Primus CapitalFrom the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
02What happenedPurpleLab raised $40M Series B, announced 2026-09-27From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
03Why it mattersPurpleLab's $40M Series B supports a healthcare data platform positioned around real-world data analysis for assessing the effectiveness of health interventions.From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗

PurpleLab · Financing Record

Explore source-linked visual explanations for PurpleLab. Unsupported claims are withheld while source review continues.

Record 12901 · Recorded date: 2026-09-27

What it does

PurpleLab: illustrative category image
Illustrative image (biotech lab), not PurpleLab's product · Stephane Lesbats (IFREMER, Pôle Images, Centre Bretagne - ZI / CC BY 4.0

Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.

Open record 12901 →

Explore company records →
Free weekday briefing

Know which funding rounds matter before the first call.

Source-linked rounds, lead investors, and the signal behind the capital. One five-minute read.

Free · Unsubscribe anytime